Phaseline

Companies › BnH Research

BnH Research: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BnH-015B
GluN2B-selective NMDA receptor positive allosteric modulator; regulates BDNF/TRKβ and micr
GRIN2B, BDNF, NTRK2Phase 1Alzheimer Disease–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06535308BnH-015BPhase 1Alzheimer DiseaseNeurologyApr 2026

Targets

GRIN2B (1) BDNF (1) NTRK2 (1)

Companies with the same targets

Praxis Precision Medicines Syndeio Biosciences GRIN Therapeutics SHINKEI Therapeutics Aptinyx Neuren Pharmaceuticals Johnson & Johnson (Janssen) SyneuRx International (Taiwan) Xuanzhu Biopharmaceutical Dompé Farmaceutici

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.